909 Walnut Street
Suite 200
Philadelphia, Pennsylvania 19107
(215) 955-7000
(215) 503-9170 fax
Suite 200
Philadelphia, Pennsylvania 19107
(215) 955-7000
(215) 503-9170 fax
Most Recent Peer-reviewed Publications
- A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury
- Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT)
- A multicenter, single-blind, prospective randomized trial to evaluate the safety of a polyethylene glycol hydrogel (duraseal dural sealant system) as a dural sealant in cranial surgery
- Nociceptive neuropeptide increases and periorbital allodynia in a model of traumatic brain injury
- Comments
- An analysis of phenytoin vs. levetiracetam for early seizure pharmacoprophylaxis following TBI
- Analysis of nonmodifiable risk factors for intracranial aneurysm rupture in a large, retrospective cohort.
- Comments
- Editorial comment
- Editorial comment
- Analysis of non-modifiable risk factors for intracranial aneurysm rupture in a large, retrospective cohort
- Comments
- Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury
- Editorial comment
- Comment
- Comments
- A murine model of hypertonic saline as a treatment for acute spinal cord injury: Effects on autonomic outcome - Laboratory investigation
- Editorial comment
- Comments
- The combination of selective inhibition of the cannabinoid CB1-, receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of Spinal Cord Injury
